UNICYCIVE THERAPEUTICS, INC. Deferred Tax Assets, Operating Loss Carryforwards
UNICYCIVE THERAPEUTICS, INC. (UNCY) had Deferred Tax Assets, Operating Loss Carryforwards of $16.65 million as of 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Operating Loss Carryforwards, Components
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-03-30
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $16.65M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $11.02M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $5.98M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $4.16M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards |
|---|---|
| 2025-12-31 | $16.65M 10-K · filed 2026-03-30 |
| 2024-12-31 | $11.02M 10-K · filed 2026-03-30 |
| 2023-12-31 | $5.98M 10-K · filed 2025-03-31 |
| 2022-12-31 | $4.16M 10-K · filed 2024-03-28 |
| 2021-12-31 | $2.26M 10-K · filed 2023-03-31 |
| 2020-12-31 | $1.07M 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |